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Reducing the Risks of Relief — The CDC's Opioid-Prescribing 
Guideline
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The annual number of deaths from prescription-opioid overdose has quadrupled in the 
United States in the past 15 years, driving dramatic increases in mortality. Efforts to improve 
pain management resulted in a quadrupling of rates of opioid prescribing, which propelled a 
tightly correlated epidemic of addiction, overdose, and death from prescription opioids that 
is now further evolving to include increasing use and overdoses of heroin and illicitly 
produced fentanyl.
The pendulum of opioid use in pain management has swung back and forth several times 
over the past 100 years. Beginning in the 1990s, efforts to improve treatment of pain failed 
to adequately take into account opioids’ addictiveness, their low therapeutic ratio, and their 
lack of documented effectiveness in the treatment of chronic pain. Increased prescribing was 
also fueled by aggressive and sometimes misleading marketing of long-acting opioids to 
physicians.1 It has become increasingly clear that opioids carry substantial risks and 
uncertain benefits, especially as compared with other treatments for chronic pain.
On March 15, 2016, the Centers for Disease Control and Prevention (CDC) released a 
“Guideline for Prescribing Opioids for Chronic Pain” to chart a safer, more effective 
course.2 The guideline is designed to support clinicians caring for patients outside the 
context of active cancer treatment or palliative or end-of-life care. More research is needed 
to fill in critical evidence gaps regarding the effectiveness, safety, and economic efficiency 
of long-term opioid therapy. However, given what we know about the risks associated with 
long-term opioid therapy and the availability of effective nonpharmacologic and nonopioid 
pharmacologic treatment options, the guideline uses the best available scientific data to 
provide information and recommendations to support patients and clinicians in balancing the 
risks of addiction and overdose with limited evidence of benefits of opioids for chronic pain.
Most placebo-controlled, randomized trials of opioids have lasted 6 weeks or less, and no 
study we are aware of has compared opioid therapy with other treatments in terms of long-
term (more-than-1-year) outcomes related to pain, function, or quality of life.2 The few 
randomized trials to evaluate opioid efficacy for longer than 6 weeks had consistently poor 
results. In fact, several studies have found that use of opioids for chronic pain may actually 
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worsen pain and functioning, possibly by potentiating pain perception. Although it was not a 
randomized, controlled trial, a 3-year prospective observational study of more than 69,000 
postmenopausal women with recurrent pain conditions found that patients who had received 
opioid therapy were less likely to have improvement in pain (odds ratio, 0.42; 95% 
confidence interval [CI], 0.36–0.49) and had worsened function (odds ratio, 1.25; 95% CI, 
1.04–1.51).3 An observational case–control study of patients undergoing orthopedic surgery 
found that those receiving long-term opioid therapy had significantly higher levels of 
preoperative hyperalgesia.4 After surgery, patients who had received long-term opioid 
therapy reported higher pain intensity (a rating of 7.6 vs. 5.5 out of 10) in the recovery room 
than patients who had not been taking opioids.
Whereas the benefits of opioids for chronic pain remain uncertain, the risks of addiction and 
overdose are clear. Although partial agonists such as buprenorphine may carry a lower risk 
of dependence, the available scientific evidence indicates that prescription opioids that are 
full mu-opioid–receptor agonists — nearly all the products on the market — are no less 
addictive than heroin. Although “abuse-deterrent” formulations may reduce the likelihood 
that patients will inject melted pills, they are no less addictive and do not prevent opioid 
abuse or fatal overdose through oral intake.
The prevalence of opioid dependence may be as high as 26% among patients in primary care 
receiving opioids for chronic non–cancer-related pain.2 Risk-stratification tools do not allow 
clinicians to predict accurately whether a patient will become addicted to opioids, although 
persons with a history of mental illness or addiction are at higher risk.2 Overdose risk 
increases in a dose–response manner, at least doubling at 50 to 99 morphine milligram 
equivalents (MME) per day and increasing by a factor of up to nine at 100 or more MME 
per day, as compared with doses of less than 20 MME per day.2 Overall, 1 of every 550 
patients started on opioid therapy died of opioid-related causes a median of 2.6 years from 
his or her first opioid prescription; the proportion was as high as 1 in 32 among patients 
receiving 200 MME or higher.5 We know of no other medication routinely used for a 
nonfatal condition that kills patients so frequently.
The CDC's new guideline emphasizes both patient care and safety. We developed the 
guideline using a rigorous process that included a systematic review of the scientific 
evidence and input from hundreds of leading experts and practitioners, other federal 
agencies, more than 150 professional and advocacy organizations, a wide range of key 
patient and provider groups, a federal advisory committee, peer reviewers, and more than 
4,000 public comments.
Three key principles underlie the guideline's 12 recommendations (see box). First, nonopioid 
therapy is preferred for chronic pain outside the contexts of active cancer, palliative, and 
end-of-life care. Opioids should be added to other treatments for chronic pain only when 
their expected benefits for both pain and function are likely to outweigh the substantial risks 
inherent in this class of medication.
Nonpharmacologic therapies can ameliorate chronic pain while posing substantially less risk 
to patients. In some instances, other therapies result in better outcomes than opioids. These 
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therapies include exercise therapy, weight loss, psychological therapies such as cognitive 
behavioral therapy, interventions to improve sleep, and certain interventional procedures. 
The evidence review conducted in developing the guideline revealed that exercise therapy 
helped improve, and sustain improvements in, pain and function in patients with 
osteoarthritis. It did not find evidence that opioids were more effective for pain reduction 
than nonopioid treatments such as nonsteroidal anti-inflammatory drugs for low back pain or 
antidepressants for neuropathic pain, but it did find that nonopioid treatments could be better 
tolerated and superior for improving physical function while conferring little or no risk of 
addiction and substantially lower risks of overdose and death.2
Second, when opioids are used, the lowest possible effective dose should be prescribed to 
reduce risks of opioid-use disorder and overdose. Clinicians should carefully reassess 
individual benefits and risk when increasing a dose to 50 MME or more per day. Doses of 90 
MME or more should be avoided, or the decision to titrate above this level should be 
carefully considered and justified. When prescribing opioids, the rule of thumb is “start low 
and go slow.”
Third, clinicians should exercise caution when prescribing opioids and monitor all patients 
closely. Prescribers should mitigate risk, for example by avoiding concurrent use of 
benzodiazepines if possible, reviewing data from a prescription-drug monitoring program 
when deciding whether to start or continue opioid therapy, offering naloxone at least to 
patients who are at greater risk for overdose, having a clear “off-ramp” plan to taper and 
discontinue therapy, reevaluating the dosage and necessity of opioid treatment regularly, and 
obtaining urine toxicology screening at the initiation of treatment and, for some patients, 
periodically thereafter.
For patients who become addicted to opioids, treatment with methadone, buprenorphine, or 
naltrexone improves outcomes. Initiation of treatment with opioids is a momentous decision 
and should be undertaken only with full understanding by both the physician and the patient 
of the substantial risks involved. Clinicians need to recognize the risk associated with any 
treatment with opioids and should prescribe only the shortest course needed. Although the 
guideline addresses chronic pain, many patients become addicted to opioids after being 
treated for acute pain. Three days of treatment or less will be often be sufficient; more than 7 
days will rarely be required. Some trauma and surgery may require longer courses; treatment 
of postsurgical pain is beyond the scope of this guideline. Furthermore, it is important to 
discuss storage of opioids in a secure location to prevent diversion, as well as to counsel 
patients regarding the overdose risk posed to household members and other persons.
Management of chronic pain is an art and a science. The science of opioids for chronic pain 
is clear: for the vast majority of patients, the known, serious, and too-often-fatal risks far 
outweigh the unproven and transient benefits.
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The CDC's Opioid-Prescribing Guideline
1. Nonpharmacologic therapy and nonopioid pharmacologic therapy are preferred 
for chronic pain. Clinicians should consider opioid therapy only if expected 
benefits for both pain and function are anticipated to outweigh risks to the 
patient. If opioids are used, they should be combined with nonpharmacologic 
therapy and nonopioid pharmacologic therapy, as appropriate.
2. Before starting opioid therapy for chronic pain, clinicians should establish 
treatment goals with all patients, including realistic goals for pain and function, 
and should consider how therapy will be discontinued if benefits do not 
outweigh risks. Clinicians should continue opioid therapy only if there is 
clinically meaningful improvement in pain and function that outweighs risks to 
patient safety.
3. Before starting and periodically during opioid therapy, clinicians should discuss 
with patients known risks and realistic benefits of opioid therapy and patient and 
provider responsibilities for managing therapy.
4. When starting opioid therapy for chronic pain, clinicians should prescribe 
immediate-release opioids instead of extended-release/long-acting (ER/LA) 
opioids.
5. When opioids are started, clinicians should prescribe the lowest effective 
dosage. Clinicians should use caution when prescribing opioids at any dosage, 
should carefully reassess evidence of individual benefits and risks when 
increasing dosage to ≥50 morphine milligram equivalents (MME) per day, and 
should avoid increasing dosage to ≥90 MME per day or carefully justify a 
decision to titrate dosage to ≥90 MME per day.
6. Long-term opioid use often begins with treatment of acute pain. When opioids 
are used for acute pain, clinicians should prescribe the lowest effective dose of 
immediate-release opioids and should prescribe no greater quantity than needed 
for the expected duration of pain severe enough to require opioids. Three days or 
less will often be sufficient; more than 7 days will rarely be needed.
7. Clinicians should evaluate benefits and harms with patients within 1–4 weeks of 
starting opioid therapy for chronic pain or of dose escalation. Clinicians should 
evaluate benefits and harms of continued therapy with patients every 3 months 
or more frequently. If benefits do not outweigh harms of continued opioid 
therapy, clinicians should optimize other therapies and work with patients to 
taper opioids to lower dosages or to taper and discontinue opioids.
8. Before starting and periodically during continuation of opioid therapy, clinicians 
should evaluate risk factors for opioid-related harms. Clinicians should 
incorporate into the management plan strategies to mitigate risk, including 
considering offering naloxone when factors that increase risk for opioid 
overdose, such as history of overdose, history of substance use disorder, higher 
opioid dosages (≥50 MME/day), or concurrent benzodiazepine use are present.
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9. Clinicians should review the patient's history of controlled substance 
prescriptions using state prescription drug monitoring program (PDMP) data to 
determine whether the patient is receiving opioid dosages or dangerous 
combinations that put him or her at high risk for overdose. Clinicians should 
review PDMP data when starting opioid therapy for chronic pain and 
periodically during opioid therapy for chronic pain, ranging from every 
prescription to every 3 months.
10. When prescribing opioids for chronic pain, clinicians should use urine drug 
testing before starting opioid therapy and consider urine drug testing at least 
annually to assess for prescribed medications as well as other controlled 
prescription drugs and illicit drugs.
11. Clinicians should avoid prescribing opioid pain medication and benzodiazepines 
concurrently whenever possible.
12. Clinicians should offer or arrange evidence-based treatment (usually 
medication-assisted treatment with buprenorphine or methadone in combination 
with behavioral therapies) for patients with opioid-use disorder.
Frieden and Houry Page 6
N Engl J Med. Author manuscript; available in PMC 2016 May 21.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
